Chinese Company Refuses GMP Inspection and Gets an Import Alert from the FDA
![Data Integrity Master Class with full-day pre-course session Raw Data](files/eca/userImages/training.img/Z-ECA-Raw-Data-Data-Integrity-Masterclass.jpg)
Recommendation
27-30 August 2024
Copenhagen, Denmark
including 8 Interactive Workshops
The US FDA has placed the Chinese company Beijing Shunxin Meihua Bio-technical Co on an import alert. Consequently, the company cannot deliver any product to the US market. According to the information portal Regulatory Focus, the import alert was published on 22 July 2014. Last year, the FDA referred to its competence in a Guideline and emphasised the fact that any refusal or obstruction to an inspection would have immediate consequences. You can read more on the topic in our GMP News "Denying, Delaying, And Refusing: How to Fail a FDA Inspection". Already in the past, a Chinese company got a Warning Letter after it had thrown three FDA inspectors out of the facility.
Related GMP News
24.07.2024FDA Warning Letter to a Manufacturer of an Athlete Muscle Maintenance Creme
24.07.2024FDA describes detailed CAPA Procedure in Warning Letter
17.07.2024Congressional Scrutiny on FDA's Foreign Inspection Program puts Pressure on Agency
19.06.2024More FDA Inspections again - also in the EU?
12.06.2024GMP Problems with critical Medicinal Products - what now?
15.05.2024Lack of Quality Oversight: EU Non-Compliance Report issued to Omeprazole Manufacturer